XWELL Completes $31.3 Million Private Placement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy XWEL?
Source: stocktwits
- Private Placement Details: XWELL signed a securities purchase agreement with American Ventures to sell 31,333 shares of Series H Preferred Stock at $1,000 each, with the transaction expected to close on February 26, 2026, and proceeds earmarked for repurchasing $6 million in notes and redeeming certain preferred shares.
- Stock Performance Recovery: XWEL shares surged above $1 for the first time since October 28, 2025, indicating a recovery after receiving a Nasdaq minimum bid price deficiency notice, as the company aims to maintain its stock price to avoid delisting risks.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', with expectations for the stock to rise to $2, reflecting increased investor confidence in the company's future performance, as the stock has gained nearly 220% year-to-date.
- Clear Use of Funds: The funds from this transaction will be used to repurchase warrants covering 8.8 million common shares for $9 million, while the remaining proceeds will support general business expenses and working capital, demonstrating the company's focus on financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XWEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XWEL
About XWEL
XWELL, Inc. is a global wellness holding company. The Company operates through four segments: XpresSpa, XpresTest, Naples Wax Center and Treat. The XpresSpa segment provides travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresCheck segment, in partnership with the Centers for Disease Control and Prevention (CDC) and Ginkgo Biosecurity, conducts biosurveillance monitoring in its airport locations. XpresTest’s HyperPointe business provides a range of service and support options for its customers, including technical support services and advanced services. The Naples Wax Center segment operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XWELL Shares Surge 221% Following $31.3 Million Private Placement Announcement
- Significant Financing: XWELL has entered into a securities purchase agreement with American Ventures to raise approximately $31.3 million through the issuance of Series H Convertible Preferred Stock, which is expected to significantly enhance the company's capital structure and liquidity.
- Stock Price Surge: XWELL shares surged 221.43% on Wednesday, closing at $1.22, reflecting strong market optimism regarding the financing, which may attract more investor interest.
- Clear Use of Proceeds: The company plans to utilize the raised funds to repurchase $5.95 million of certain notes and redeem its Series G preferred stock, with a total cash outlay of $9 million, which will help reduce financial costs and optimize its capital structure.
- Transaction Completion Imminent: The private placement is anticipated to close on or around Thursday, further boosting market confidence in XWELL's future growth potential and potentially laying a solid foundation for the company's subsequent development.
See More
XWELL Completes $31.3 Million Private Placement
- Private Placement Details: XWELL signed a securities purchase agreement with American Ventures to sell 31,333 shares of Series H Preferred Stock at $1,000 each, with the transaction expected to close on February 26, 2026, and proceeds earmarked for repurchasing $6 million in notes and redeeming certain preferred shares.
- Stock Performance Recovery: XWEL shares surged above $1 for the first time since October 28, 2025, indicating a recovery after receiving a Nasdaq minimum bid price deficiency notice, as the company aims to maintain its stock price to avoid delisting risks.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', with expectations for the stock to rise to $2, reflecting increased investor confidence in the company's future performance, as the stock has gained nearly 220% year-to-date.
- Clear Use of Funds: The funds from this transaction will be used to repurchase warrants covering 8.8 million common shares for $9 million, while the remaining proceeds will support general business expenses and working capital, demonstrating the company's focus on financial health.
See More
U.S. Stocks Rise as TJX Reports Strong Earnings Beat
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 250 points, indicating improved market sentiment, particularly as technology shares increased by 1.6%, reflecting heightened investor confidence in the tech sector.
- TJX Earnings Report: TJX Companies reported fourth-quarter earnings of $1.43 per share, surpassing analyst expectations of $1.39, with sales reaching $17.743 billion, also exceeding the consensus estimate of $17.370 billion, showcasing the company's robust performance in retail.
- Future Outlook: Despite TJX's FY2027 GAAP EPS guidance of $4.93 to $5.02 falling short of the market estimate of $5.17, the strong quarterly results may still attract investor interest, reflecting the company's resilience in an uncertain market environment.
- Economic Data: The volume of mortgage applications in the U.S. increased by 0.4% in the third week of February, although this was lower than the previous week's 2.8% gain, indicating a gradual recovery in the housing market that could positively impact future economic growth.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 200 Points
- Strong Dow Performance: The Dow Jones index gained over 200 points on Wednesday, rising 0.41% to close at 49,375.99, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ surged 0.77% to 23,040.20, while the S&P 500 rose 0.55% to 6,928.15, reflecting strong performances in technology and other major sectors.
- Lowe's Earnings Beat Expectations: Lowe's reported Q4 earnings of $1.98 per share, exceeding analyst expectations of $1.94, with sales of $20.584 billion also surpassing the consensus estimate of $20.334 billion, although the company issued weaker future earnings guidance.
- Energy Stocks Decline: Energy stocks fell by 0.3% on Wednesday, contrasting with a 0.8% rise in information technology shares, indicating a divergence in market performance that could influence investor asset allocation strategies.
See More
Totaligent Forms Joint Venture with GloMed for Biologics Distribution
- Strategic Partnership: Totaligent has signed a binding Letter of Intent with Japan's GloMed Solutions to establish a joint venture that integrates Totaligent's Aetherium medical platform with GloMed's distribution infrastructure, aiming to accelerate biologics adoption in the APAC market, with the transaction expected to close in approximately four weeks.
- Capital Structure Reset: XWELL announced a $31.3 million private placement aimed at repurchasing $5.96 million in outstanding notes and redeeming Series G Preferred Stock, indicating a strategic effort to simplify its balance sheet, with closing expected around February 26.
- AI Drug Discovery Validation: Recursion Pharmaceuticals reported Q4 and full-year 2025 results, highlighting clinical validation of its AI-driven drug discovery platform, with REC-4881 showing 75% efficacy in familial adenomatous polyposis patients, reinforcing the company's leadership in the biotech sector.
- Revenue Growth Expectations: NextPlat projects approximately $55 million in revenue for 2025, with Q4 340B revenue expected to increase over 90%, and anticipates gross margin expansion of 20%-25% in 2026, reflecting a strategic shift towards revenue quality and cost control.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
XWELL Shares Surge 221% Following $31.3 Million Private Placement Announcement
- Significant Financing: XWELL has entered into a securities purchase agreement with American Ventures to raise approximately $31.3 million through the issuance of Series H Convertible Preferred Stock, which is expected to significantly enhance the company's capital structure and liquidity.
- Stock Price Surge: XWELL shares surged 221.43% on Wednesday, closing at $1.22, reflecting strong market optimism regarding the financing, which may attract more investor interest.
- Clear Use of Proceeds: The company plans to utilize the raised funds to repurchase $5.95 million of certain notes and redeem its Series G preferred stock, with a total cash outlay of $9 million, which will help reduce financial costs and optimize its capital structure.
- Transaction Completion Imminent: The private placement is anticipated to close on or around Thursday, further boosting market confidence in XWELL's future growth potential and potentially laying a solid foundation for the company's subsequent development.
See More
XWELL Completes $31.3 Million Private Placement
- Private Placement Details: XWELL signed a securities purchase agreement with American Ventures to sell 31,333 shares of Series H Preferred Stock at $1,000 each, with the transaction expected to close on February 26, 2026, and proceeds earmarked for repurchasing $6 million in notes and redeeming certain preferred shares.
- Stock Performance Recovery: XWEL shares surged above $1 for the first time since October 28, 2025, indicating a recovery after receiving a Nasdaq minimum bid price deficiency notice, as the company aims to maintain its stock price to avoid delisting risks.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', with expectations for the stock to rise to $2, reflecting increased investor confidence in the company's future performance, as the stock has gained nearly 220% year-to-date.
- Clear Use of Funds: The funds from this transaction will be used to repurchase warrants covering 8.8 million common shares for $9 million, while the remaining proceeds will support general business expenses and working capital, demonstrating the company's focus on financial health.
See More
U.S. Stocks Rise as TJX Reports Strong Earnings Beat
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 250 points, indicating improved market sentiment, particularly as technology shares increased by 1.6%, reflecting heightened investor confidence in the tech sector.
- TJX Earnings Report: TJX Companies reported fourth-quarter earnings of $1.43 per share, surpassing analyst expectations of $1.39, with sales reaching $17.743 billion, also exceeding the consensus estimate of $17.370 billion, showcasing the company's robust performance in retail.
- Future Outlook: Despite TJX's FY2027 GAAP EPS guidance of $4.93 to $5.02 falling short of the market estimate of $5.17, the strong quarterly results may still attract investor interest, reflecting the company's resilience in an uncertain market environment.
- Economic Data: The volume of mortgage applications in the U.S. increased by 0.4% in the third week of February, although this was lower than the previous week's 2.8% gain, indicating a gradual recovery in the housing market that could positively impact future economic growth.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 200 Points
- Strong Dow Performance: The Dow Jones index gained over 200 points on Wednesday, rising 0.41% to close at 49,375.99, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ surged 0.77% to 23,040.20, while the S&P 500 rose 0.55% to 6,928.15, reflecting strong performances in technology and other major sectors.
- Lowe's Earnings Beat Expectations: Lowe's reported Q4 earnings of $1.98 per share, exceeding analyst expectations of $1.94, with sales of $20.584 billion also surpassing the consensus estimate of $20.334 billion, although the company issued weaker future earnings guidance.
- Energy Stocks Decline: Energy stocks fell by 0.3% on Wednesday, contrasting with a 0.8% rise in information technology shares, indicating a divergence in market performance that could influence investor asset allocation strategies.
See More
Totaligent Forms Joint Venture with GloMed for Biologics Distribution
- Strategic Partnership: Totaligent has signed a binding Letter of Intent with Japan's GloMed Solutions to establish a joint venture that integrates Totaligent's Aetherium medical platform with GloMed's distribution infrastructure, aiming to accelerate biologics adoption in the APAC market, with the transaction expected to close in approximately four weeks.
- Capital Structure Reset: XWELL announced a $31.3 million private placement aimed at repurchasing $5.96 million in outstanding notes and redeeming Series G Preferred Stock, indicating a strategic effort to simplify its balance sheet, with closing expected around February 26.
- AI Drug Discovery Validation: Recursion Pharmaceuticals reported Q4 and full-year 2025 results, highlighting clinical validation of its AI-driven drug discovery platform, with REC-4881 showing 75% efficacy in familial adenomatous polyposis patients, reinforcing the company's leadership in the biotech sector.
- Revenue Growth Expectations: NextPlat projects approximately $55 million in revenue for 2025, with Q4 340B revenue expected to increase over 90%, and anticipates gross margin expansion of 20%-25% in 2026, reflecting a strategic shift towards revenue quality and cost control.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
